Below, you can find the biggest H1 2025 funding rounds in Serbia, along with key details about the startups. Check the rest of the Central and Eastern Europe H1 2025 mappings here.
This article is part of the CEE funding mapping series, done with the support of Dealigence platform. Please feel free to contact us if we missed something: [email protected]. / If the deal’s original currency wasn’t the euro, we convert it to the ratio listed on the publishing day.
Serbia H1 2025 Funding
nextesy
(Swiss based; Serbian and Bosnian founded)
About: An enterprise operating system provides solutions and tools for organizations to streamline processes, enhance collaboration, and leverage data for insights and decision-making, fostering growth and transformation in a connected business environment.
Founders: Aleks Grujić; Dario Fazlić; Milan Kuzmanović; Stefan Mitrović; Miloš Čalija
Vertical: Business Process Management, AI, SaaS
Latest round: €3.5M
Stage: Seed
Investors: SICTIC; Fifth Quarter Ventures
Total funding: €3.16M
Prepia
About: Offers a mobile-first learning platform that helps professionals in the U.S. prepare for over 100 healthcare and IT certification exams through personalized, interactive AI-driven content.
Founders: Viktor Pešić, Ivan Jurišić
Vertical: Education
Latest round: €1.5M
Stage: Seed
Investors: Inovo VC, Silicon Gardens
Total funding: €1.5M
Veli
About: A digital asset investment platform that enables financial advisors to onboard clients and manage portfolios with offerings such as cryptocurrencies, crypto strategies, and tokenized assets, along with expert support and educational resources.
Founders: Stevan Radonjanin; Marko Selaković
Vertical: Finance; Blockchain
Latest round: €100K
Stage: Seed
Investors: Omorika Ventures; Digital Serbia initiative
Total funding: €273K
Other important deals
In May 2025, the business angel network of the Digital Serbia Initiative has invested in Vinaver Medical, a local startup developing software solutions to enhance medical diagnostics and therapy planning in oncology using artificial intelligence and spectral CT technology.
In March 2025, Emergent BioSolutions Inc., a leading public health company has completed a strategic financial investment into Swiss Rockets, the parent company of Rocketvax, founded by Vladimir Cmiljanovic, Natasa Cmiljanovic and Manuel Ebner. The funds will be used to support research, infrastructure development, and the expansion of Swiss Rockets’ biotechnology portfolio. In addition to the investment, the parties intend to form a strategic partnership whereby Emergent would lead the U.S. manufacturing and commercialization efforts for four of Rocketvax’s pipeline candidates for infectious diseases, cancer, and autoimmune disorders.
